Big drugmakers aren’t doing as big deals as they had, mostly doing less risky bolt-ons under $10 billion

About three-quarters of pharmaceutical deals this year have been between $1 billion and $10 billion.

Discover more from RealUS.news

Subscribe now to keep reading and get access to the full archive.

Continue reading